Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 14Fallopian Tube Neoplasms 8Uterine Cervical Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Endometrial Adenocarcinoma 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × cediranib × Gynecologic × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡